Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
In vivo mallard experiments indicate that zanamivir has less potential for environmental influenza A virus resistance development than oseltamivir
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Infectious Diseases.
Umeå University, Department of Public Health and Clinical Medicine, Occupational and Environmental Medicine.
Umeå University, Department of Chemistry.
Show others and affiliations
2017 (English)In: Journal of General Virology, ISSN 0022-1317, E-ISSN 1465-2099, Vol. 98, no 12, p. 2937-2949Article in journal (Refereed) Published
Abstract [en]

Neuraminidase inhibitors are a cornerstone of influenza pandemic preparedness before vaccines can be mass-produced and thus a neuraminidase inhibitor-resistant pandemic is a serious threat to public health. Earlier work has demonstrated the potential for development and persistence of oseltamivir resistance in influenza A viruses exposed to environmentally relevant water concentrations of the drug when infecting mallards, the natural influenza reservoir that serves as the genetic base for human pandemics. As zanamivir is the major second-line neuraminidase inhibitor treatment, this study aimed to assess the potential for development and persistence of zanamivir resistance in an in vivo mallard model; especially important as zanamivir will probably be increasingly used. Our results indicate less potential for development and persistence of resistance due to zanamivir than oseltamivir in an environmental setting. This conclusion is based on: (1) the lower increase in zanamivir IC50 conferred by the mutations caused by zanamivir exposure (2-17-fold); (2) the higher zanamivir water concentration needed to induce resistance (at least 10 µg l-1); (3) the lack of zanamivir resistance persistence without drug pressure; and (4) the multiple resistance-related substitutions seen during zanamivir exposure (V116A, A138V, R152K, T157I and D199G) suggesting lack of one straight-forward evolutionary path to resistance. Our study also adds further evidence regarding the stability of the oseltamivir-induced substitution H275Y without drug pressure, and demonstrates the ability of a H275Y-carrying virus to acquire secondary mutations, further boosting oseltamivir resistance when exposed to zanamivir. Similar studies using influenza A viruses of the N2-phylogenetic group of neuraminidases are recommended.

Place, publisher, year, edition, pages
2017. Vol. 98, no 12, p. 2937-2949
National Category
Microbiology in the medical area
Identifiers
URN: urn:nbn:se:uu:diva-341700DOI: 10.1099/jgv.0.000977ISI: 000417312300007PubMedID: 29139346OAI: oai:DiVA.org:uu-341700DiVA, id: diva2:1182311
Funder
Swedish Research Council Formas, 211-2013-1320 2016-00790Swedish Research Council, 2016-02606Available from: 2018-02-12 Created: 2018-02-12 Last updated: 2020-05-08Bibliographically approved
In thesis
1. Prescription – Pollution – Poo – Pandemics - Priorities: Neuraminidase Inhibitors from an Environmental Resistance Development Perspective
Open this publication in new window or tab >>Prescription – Pollution – Poo – Pandemics - Priorities: Neuraminidase Inhibitors from an Environmental Resistance Development Perspective
2018 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

The natural Influenza A virus (IAV) host is waterfowl. Human IAV is treated with neuraminidase inhibitors (NAIs), which are stockpiled worldwide in case of an IAV pandemic. As the drugs escape regular waste water treatment, they can be detected in river waters.

We hypothesize that exposure of low pathogenic avian IAV (LPAIV) infecting Mallards to NAIs in the water promotes development of resistance that can persist in the absence of drugs. Dissemination of resistance genes to humans pose a health risk, particularly if incorporated into a pandemic IAV.

To test the hypothesis, LPAIVs of both NA phylogenetic groups were assessed in an in vivo Mallard model by inoculation and exposure of birds to NAI in their water. In previous work in the model, the oseltamivir-resistant H275Y mutation emerged in H1N1 in response to oseltamivir exposure and persisted without drug pressure.

In this thesis, a H7N9 was exposed to oseltamivir and a H1N1 and H4N2 to zanamivir and peramivir. Furthermore, a H1N1 with the H275Y mutation was exposed to zanamivir in order to assess the additional development of zanamivir resistance and the persistence of the H275Y mutation in the presence of zanamivir.

Several substitutions reducing drug susceptibility emerged; I222T in H7N9, V116A, A138V, T157I, R152K and D199G in H1N1 exposed to zanamivir, H275N and E119G in H4N2 exposed to zanamivir and 275Y in H4N2 exposed to peramivir. None of the tested zanamivir-induced substitutions persisted in the absence of drug, indicating lower risk of circulation of these substitutions in the wild as compared to oseltamivir.

There is a risk of NAI resistance emerging in LPAIVs of Mallards exposed to NAIs in the water. Zanamivir appears to be the best option from an environmental perspective. Drug concentrations in the Mallard model are mostly higher than the concentrations detected in rivers, but are in the same magnitude regarding OC and an H1N1 LPAIV. Given the importance of NAIs as the first line of defence in the event of a pandemic, this is of public health concern. Surveillance of LPAIV in waterfowl, prudent use of NAIs and waste water treatment improvements are important measures to mitigate the risk.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2018. p. 74
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 1428
Keywords
Influenza A virus, neuraminidase inhibitor, resistance, environmental, Mallard, zanamivir, avian influenza
National Category
Medical and Health Sciences Agricultural and Veterinary sciences
Identifiers
urn:nbn:se:uu:diva-341701 (URN)978-91-513-0237-9 (ISBN)
Public defence
2018-03-29, Auditorium Minus, Museum Gustavianum, Akademigatan 3, Uppsala, 09:15 (Swedish)
Opponent
Supervisors
Available from: 2018-03-07 Created: 2018-02-14 Last updated: 2018-04-03

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Nykvist, MarieGillman, AnnaLundkvist, ÅkeWille, MichelleJärhult, Josef D.

Search in DiVA

By author/editor
Nykvist, MarieGillman, AnnaLundkvist, ÅkeWille, MichelleJärhult, Josef D.
By organisation
Department of Medical Biochemistry and MicrobiologyInfectious Diseases
In the same journal
Journal of General Virology
Microbiology in the medical area

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 223 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf